The activities of current antimalarial drugs on the life cycle stages of Plasmodium: a comparative study with human and rodent parasites.

Delves M, Plouffe D, Scheurer C, Meister S, Wittlin S, Winzeler EA, Sinden RE, Leroy D. · 2012

Read The activities of current antimalarial drugs on the life cycle stages of Plasmodium: a comparative study with human and rodent parasites. by Delves M, Plouffe D, Scheurer C, Meister S, Wittlin S, Winzeler EA, Sinden RE, Leroy D. (2012) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc3283556.txt.

Introduction

Michael Delves and colleagues compared how current and experimental malaria drugs perform across the parasite's whole life cycle, in this 2012 paper in PLoS Medicine. Most drug testing concentrates on the blood stages that cause illness, yet malaria parasites also pass through liver stages in people and sexual stages that mosquitoes pick up. A drug blind to those stages cannot fully block transmission or prevent relapse.

The team tested fifty antimalarial compounds against the liver stage, the sexual blood stages, and the mosquito stages. Several Plasmodium species were used, including the main human parasite and two rodent parasites serving as laboratory stand-ins. Running the same panel across species and stages exposes which drugs work only on blood stages and which cover the full cycle. The authors offer the comparison as a guide for developing medicines that cure, prevent, and interrupt transmission at once.

Catalog record

CREATORDelves M, Plouffe D, Scheurer C, Meister S, Wittlin S, Winzeler EA, Sinden RE, Leroy D.
YEAR2012
COLLECTIONPAPERS
FORMATTXT
FILE SIZE54 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC3283556

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

The Activities of Current Antimalarial Drugs on the Life Cycle Stages of Plasmodium: A Comparative Study with Human and Rodent Parasites By Michael Delves, David Plouffe, Christian Scheurer, Stephan Meister, Sergio Wittlin, Elizabeth A. Winzeler, Robert E. Sinden, Didier Leroy, James G. Beeson Published in: PLoS Medicine DOI: 10.1371/journal.pmed.1001169 ABSTRACT Michael Delves and colleagues compare the activity of 50 current and experimental antimalarials against liver, sexual blood, and mosquito stages of selected human and nonhuman parasite species, including Plasmodium falciparum, Plasmodium berghei, and Plasmodium yoelii. INTRODUCTION Malaria remains one of the most widespread infectious diseases of our time. The latest estimates reveal that ∼250 million people are infected with malaria across the globe, of whom ∼800,000 die every year [1], the vast majority being young children. In 2007, the malaria eradication agenda was adopted by many researchers in the antimalarial community and target product profiles for new antimalarial medicines were defined [2]. Most available antimalarials were designed to target the pathogenic blood stages in humans and to address the constant threat of drug resistance [3]. However, to meet the objective of malaria eradication, medicines that block parasite transmission [4] and eliminate the asymptomatic and sometimes cryptic hepatic forms also need to be developed. The bottleneck populations of liver and sexual stage parasites [5] represent potential pathogen vulnerabilities that could be targeted by small molecules; the first such bottleneck is at the liver stage. Within minutes of being released by the bite of an infected female Anopheles mosquito, Plasmodium sporozoites reach the mammalian liver, where they invade hepatocytes and either lie dormant or develop over several days, eventually forming the schizonts that are the prelude to a blood stage infection [6]. Molecules that efficiently target the parasite stages in the liver would offer protection from infection and could theoretically eliminate the cryptic hypnozoite (dormant parasite) infection reservoirs formed by P. vivax and P. ovale. Because only 100 or so sporozoites may be introduced by a bite, there are likely to be many orders of magnitude fewer parasites at this stage than in an active blood stage infection, reducing the possibility of resistance arising. A second bottleneck occurs during sexual development. At each round of schizogony ∼1% of merozoites differentiate into gametocytes [7], and it is these developmentally arrested cells that are transmitted to the mosquito. Mature gametocytes are sexually dimorphic, forming microgametocytes and macrogametocytes that escape the red blood cell (RBC) and produce male and female gametes in the blood meal of the mosquito by processes known as exflagellation [8] and activation, respectively. Following fertilization the zygote differentiates into a motile and invasive ookinete within which the briefly diploid genome undergoes meiosis. These processes occur within an environment almost totally derived from host blood, which can therefore provide a novel and ideal conduit for the delivery of drugs to inhibit parasite transmission to the mosquito. Having crossed the mosquito midgut wall [9], the very few surviving ookinetes differentiate into oocysts, which undergo endomitosis, eventually producing thousands of daughter sporozoites. The sporozoites migrate from the midgut of the mosquito to its salivary glands where the lifecycle begins again. Given that it would be highly desirable for candidate drugs to have activity against hepatic and sexual forms of the malarial parasite, it is surprising that few clinical trials, to date, have examined whether gametocyte carriage can be reduced following drug treatment. The only drugs found to be effective at reducing gametocyte carriage include artemisinin [10], artemisinin combination therapies (ACTs) [11],[12], methylene blue [13], and primaquine [12],[14]. Additionally, few studies have investigated the impact of drugs on the transmission of parasites from human blood to the mosquito vector [15]–[18], nor have many been designed to evaluate antihepatic stage activity. In the context of malaria eradication these gaps in our understanding of the full potential of the drug armoury are problematic. Here we report the development of a series of novel assays against liver, sexual blood, and mosquito stages of the malaria parasite, using both drug-susceptible and drug-resistant parasite strains. We applied these assays to the current portfolio of schizonticidal compounds, consisting of 50 anti-infectives currently in use or under development.. METHODS Ethics Statement All work involving laboratory animals for the host-to-mosquito transmission studies was performed in accordance with the European Union (EU) regulations “EU Directive 86/609/EEC” and within the regulations of the United Kingdom Animals (Scientific Procedures) Act 1986, sanctioned by UK Home Office Licence PLL70/6347 awarded in January 2008. Protocol design and implementation was guided by the principle of the three Rs (reduction, refinement, and replacement) and are of mild-to-moderate severity. Protocols are regularly reviewed and revised following approval by the Imperial College Ethics Review Committee. Parasite Maintenance P. berghei parasites constitutively expressing GFP (PbGFPcon) [19]–[21] were routinely maintained as described previously [22]. Only blood showing exflagellating parasites was used in the transmission assays. P. falciparum NF54 strain parasites were maintained in culture as described previously [23]. Gametocyte cultures were produced as described [24]. P. falciparum In Vitro Antimalarial Activity In vitro antimalarial activity was measured using the [3H]-hypoxanthine incorporation assay [25] with various strains of P. falciparum obtained from MR4. Results were expressed as the concentration resulting in 50% inhibition (IC50). P. falciparum Exflagellation Assay Compounds were added to mature gametocyte of drug-sensitive P. falciparum cultures that showed the ability to exflagellate. After 24 h, exflagellation was triggered by a temperature decrease to ∼21°C and observed 20 min later under the microscope. Highly motile exflagellation centres were recorded for ∼50–150 adjacent fields of view and reported per 10,000 RBCs. P. berghei Ookinete Development Assay – Slide Method Compounds and P. berghei gametocyte-infected blood were dispensed in a 96-well plate containing ookinete medium [26]. After 24 h at 19°C, Giemsa-stained ookinetes were counted under the microscope (×40) as previously described [27],[28]. Standard Membrane Feed Assay – P. berghei Membrane feeds were performed as described previously [22]. Briefly, PbGFPcon-infected mouse blood was mixed with compounds, immediately placed into membrane feeders (39°C) and offered for 30 min to 80–100 overnight-starved A. stephensi (SDA 500 strain). After 7–9 d at 19°C/80%RH, mosquito midguts were dissected out. Midguts were fixed with paraformaldehyde and oocyst number was determined microscopically by semi-automated analysis as previously described [29]. Standard Membrane Feed Assay – P. falciparum Gametocyte cultures were produced according to the same protocol as the Pf exflagellation assay. Pooled gametocyte cultures [30] were evenly divided between compounds in fresh medium and incubated at 37°C for 24 h. The parasite pellets were then resuspended in fresh RBCs and human serum treated with the compounds to a 50% haematocrit and immediately fed to mosquitoes as described above and then maintained at 27°C/60%RH for 10–12 d before dissection and counting. Liver Stage Assay 7.5×103 HepG2 cells in 50 µl of medium (1.5×105 cells/ml) were seeded in 384 well plates (Aurora 384 IQ-EB Black/Clear Plates) 20–26 h prior to the actual infection [31]. 2 h prior to infection, 50 nl of compound in DMSO (0.1% final DMSO concentration per well) were transferred with a PinTool (GNF Systems) into the assay plates (10 µM final concentration). P. yoelii sporozoites were freshly dissected from infected A. stephensi mosquito salivary glands and filtered twice with a 40-µm strainer. The HepG2 cells were then infected with 8×103

Read the complete text